What Is Agomelatine?

Agomelatine is an agonist of the melatonin receptors (MT1 and MT2) and an antagonist of the serotonin receptors (5HTC). Agomelatine was initially developed in 1997 and was granted authorization for medical use in the European Union in 2009 and Australia in 2010. [R]

Multiple trials have shown that Agomelatine could potentially be an effective treatment for major depressive disorder. Agomelatine has also shown its potential efficacy in preventing the relapse of depression. Plus, it has demonstrated potential good tolerability compared with widely-used antidepressants.

Agomelatine has also displayed the potential ability for anxiolytic properties in animal models of depression. Aside from that, it resynchronized circadian rhythms in a dose-dependent manner. These findings suggest that Agomelatine may have the potential to promote sleep and reset the biological clock in humans. [R]

How does Agomelatine Work?

Agomelatine binds with melatonin receptors (MT1 and MT2) to potentially stimulate the release of melatonin. It may also stop the action of serotonin receptors (5HTC), which could stimulate the release of norepinephrine and dopamine (it would not affect serotonin levels). [R]

Its mechanisms of action are different from that of existing antidepressants. While Agomelatine could primarily act via the melatonergic and serotonergic pathways, most antidepressants you see on the market act via monoaminergic (monoamine) mechanisms. [R]

This difference in their working mechanisms is noteworthy. A report prepared by the European Medicines Agency (EMA) as well as a meta-analysis of 20 trials indicate that Agomelatine poses a relatively small risk of potential severe side effects as opposed to standard antidepressants. [R]

Agomelatine Research

Multiple large-scale, randomized clinical trials have been conducted on Agomelatine. This research chemical has also attracted numerous animal and cell-based studies. All these trials and studies have demonstrated that Agomelatine possesses enormous potential as an antidepressant.

1. Agomelatine and Major Depressive Disorder

Ten placebo-controlled trials were conducted to investigate the short-term efficacy of Agomelatine in major depressive disorder in adults. At the end of the trials (over 6 or 8 weeks), Agomelatine had demonstrated potential significant efficacy in 6 out of the ten trials. [R]

A meta-analysis of 20 trials with more than 7,400 participants concluded that Agomelatine is a potential effective antidepressant with similar efficacy to standard antidepressants. The trial’s results also show that Agomelatine may pose a relatively small risk of sexual side effects. [R]

Another placebo-controlled trial demonstrated that Agomelatine could potentially successfully prevented relapse in more than two-thirds (78%) of the patients. The incidence of relapse during the 6-month follow-up period was potentially a 22% and 47% for Agomelatine and placebo, respectively.

2. Agomelatine and Anxiety

A 2005 study found that Agomelatine may potentially elicit anxiety-relieving properties in rats. The anxiolytic effects produced by Agomelatine were comparable to those induced by clorazepate, a clinically approved compound to treat anxiety, even though Agomelatine had a different mechanism of action. [R]

A relatively recent study has demonstrated how Agomelatine canpotentially relieve anxiety. It has shown that Agomelatine blocks a receptor in nerve cells (5HT2C) which could potentially play a role in causing anxiety. In addition, Agomelatine may activate the MT receptor, which is known for keeping anxiety in check. [R]

The researchers also concluded that Agomelatine’s potential anxiolytic effects are caused by mechanisms that are distinct from those of other non-controlled prescription drugs currently used to treat General Anxiety Disorder (GAD).

3. Agomelatine and Cognition

In a 2017 animal study, Agomelatine was effective in alleviating stress-induced cognitive impairments in mice. This research chemical was also shown to reverse gene-related effects of stress. Plus, Agomelatine significantly reversed the memory impairments caused by stress in mice. [R]

Another study was conducted to investigate the chronic effects of Agomelatine administration on the cognitive performance of rats. It was noted that the memory performance of rats during one of the study’s trials was significantly better than that of the controls. [R]

In addition, Agomelatine-treated animals achieved a better learning index. These data provide evidence that Agomelatine has beneficial effects on the cognitive parameters of animals.

4. Agomelatine and Sleep

An analysis of the effects of Agomelatine on sleep indicates that this antidepressant produces subjective and objective potential improvements in sleep. Agomelatine may potentially increase slow-wave sleep and improve sleep wave quality, with little to no effect whatsoever on REM sleep. [R]

It has also been shown that when taken at night, Agomelatine could potentially improve sleep quality by mimicking the natural rhythm of melatonin release. Furthermore, it can have the potential ability to restore non-rapid-eye movement-rapid-eye movement (NREM-REM) sleep stage cycles within nighttime sleep.

Agomelatine has also been shown to have the potential to improve all aspects of the sleep-wake cycle in depressed patients. This antidepressant has demonstrated an potential improvement in the quality of sleep and daytime alertness, with its effects kicking off as early as 1 week in randomized trial patients. [R]

5. Agomelatine and Autism

Agomelatine has shown an ameliorative effect on behavioral, neurochemical, and blood-brain barrier alteration in animals with an induced autism spectrum disorder. Thus, it may provide a potential  beneficial therapeutic strategy for managing autism spectrum disorder. [R]

Agomelatine may also potentially help reduce sleep disturbances in adults with ASD. A randomized clinical trial reached this conclusion after administering Agomelatine to 25 adults with ASD. All the study’s participants received 25mg/day of Agomelatine or placebo for 3 months. [R]

Lastly, a case study shows that 3-week Agomelatine treatment had potentially reduced hyperactivity, irritability, and sleep pattern disturbances in a 10-year-old kid with ASD. The response was well-maintained at week-6 and 12. Agomelatine could thus address behavioral facets in ASD. [R]

6. Agomelatine and Neurogenesis

Neurogenesis is the process by which new nerve cells are formed in the brain. Research has shown that neurogenesis preserves cognitive functioning. It also plays a vital role in neural plasticity and the repair of damaged brain cells affected by aging and brain disorders. [R]

Data from an animal study provides evidence that Agomelatine may promote adult hippocampal neurogenesis in chronically stressed rats. This is encouraging given that hippocampal neurogenesis has been established in different species, including humans. [R][R]

7. Agomelatine and Sexual Function

In a large-scale, randomized, placebo-controlled trial, twice as many depressed patients reported a potential deterioration of sexual function with Venlafaxine compared with Agomelatine. In fact, the rate of sexual dysfunction was similar between the placebo and Agomelatine groups.

On the basis of this data, it can be suggested that treatment with Agomelatine is potentially associated with a lower risk of sexual dysfunction compared with that of first-line antidepressants, which you can buy from any online pharmacy of your choice. [R]

8. Agomelatine and Alzheimer’s Disease

A rat study was conducted to investigate the potential neuroprotective effect of Agomelatine in Alzheimer’s disease (AD). It was found that Agomelatine attenuated spatial memory deficit, amyloid-B deposition, and neuroinflammation in the mice’s hippocampus. [R]

Based on the results, Agomelatine could become a promising treatment compound candidate in AD therapy.

9. Agomelatine and Chronic Kidney Disease

In a rat model, Agomelatine protected against obesity-induced renal injury (severe renal insufficiency) by ameliorating insulin resistance and renal dysfunction. It did that by improving renal functions through the modulation of oxidative stress, apoptosis (cell death), and ER stress. [R]

Agomelatine Side Effects

Side effects of Agomelatine could potentially include abdominal pain, insomnia, drowsiness, dizziness, and increased body weight. There has been no evidence of therapeutic compound interactions with Agomelatine when given concurrently with other SSRIs. A missed dose may not cause any adverse reactions. [R][R]

Pure Rawz sells Agomelatine for laboratory and research use only.

Where to Buy Agomelatine?

Pure Rawz is the best place to buy Agomelatine online.

In order to be the best supplier of research chemicals, we provide reference materials with every product we sell. All of our products come with an independent, third-party-issued Certificate of Analysis for identification, purity, and concentration.

We offer free international shipping on all orders above $100. You can pay for your purchase through various methods, including PayPal and Bitcoin. Click on the ‘Reviews’ tab to check out what existing customers have to say about our products and great customer service.

Agomelatine Summary

Multiple large-scale trials have established that Agomelatine could potentially be an effective treatment for major depressive disorder in adults. This melatonin analog has also shown promising anxiolytic, sleep-enhancing, and neuroprotective effects in animal studies.

Pure Rawz only sells research chemicals and no regular or herbal medication. All the information given above is intended for educational purposes. Agomelatine for sale is not for human consumption.